Med-Chemist : "Quintessential Medicinal Chemistry"
Tuesday, May 19, 2015
New cancer drug enters phase I clinical trials in humans
›
"Even though they have elevated levels of procaspase-3, cancer cells never turn the enzyme on. So they keep growing and become tumo...
Monday, May 18, 2015
EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC
›
Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Friday, May 15, 2015
EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease
›
Tolvaptan ( INN ), also known as OPC-41061, is a selective, competitive vasopressin receptor 2 antagonist used to treat hypona...
Thursday, May 14, 2015
Study shows efficacy of YONDELIS (trabectedin) in patients with soft-tissue sarcoma
›
In continuation of my update on trabectedin PharmaMar announced that the European Journal of Cancer published online data from...
Wednesday, May 13, 2015
Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium
›
Bionomics Limited (ASX:BNO, ADR:BMICY) is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients wi...
Tuesday, May 12, 2015
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer
›
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvan...
Treatment reduces risk of recurrence of C. difficile infection
›
In continuation of my update on metronidazole & vancomycin Among patients with Clostridium difficile infection (CDI) wh...
Monday, May 11, 2015
Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA
›
Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102...
Friday, May 8, 2015
Anticoagulant fondaparinux lowers risk of major bleeding events, death in heart attack patients
›
Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bl...
Thursday, May 7, 2015
New compound appears to play role in development of opioid tolerance
›
While opioids are a widely used treatment for pain, patients who take them on a regular basis can become tolerant, requiring a higher dose...
Wednesday, May 6, 2015
Alcon Receives FDA Approval of Pazeo (olopatadine HCl) Ophthalmic Solution for Allergic Conjunctivitis
›
Olopatadine hydrochloride is an antihistamine (as well as anticholinergic and mast cell stabilizer), sold as a prescriptio...
Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1
›
In continuation of my update on eliglustat Among previously untreated adults with Gaucher disease type 1, a genet...
Tuesday, May 5, 2015
New molecule shows promise in controlling HIV without using daily antiretroviral drugs
›
Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wid...
Monday, May 4, 2015
Eli Lilly accepts committee recommendation to extend evacetrapib Phase 3 trial
›
We know that, Evacetrapib is a drug under development by Eli Lilly and company (investigational name LY2484595 ) ...
Friday, May 1, 2015
Palbociclib extends progression-free survival in advanced breast cancer patients
›
In continuation of my update on Palbociclib Palbociclib, an investigational oral medication that works by blocking molecules responsib...
‹
›
Home
View web version